![IJMS | Free Full-Text | Identification of a Reliable Biomarker Profile for the Diagnosis of Gaucher Disease Type 1 Patients Using a Mass Spectrometry-Based Metabolomic Approach IJMS | Free Full-Text | Identification of a Reliable Biomarker Profile for the Diagnosis of Gaucher Disease Type 1 Patients Using a Mass Spectrometry-Based Metabolomic Approach](https://pub.mdpi-res.com/ijms/ijms-21-07869/article_deploy/html/images/ijms-21-07869-ag.png?1606399408)
IJMS | Free Full-Text | Identification of a Reliable Biomarker Profile for the Diagnosis of Gaucher Disease Type 1 Patients Using a Mass Spectrometry-Based Metabolomic Approach
![Tengo Gaucher. No pienso en mañana, si me levanto bien disfruto y punto" | Noticias de Salud en Heraldo.es Tengo Gaucher. No pienso en mañana, si me levanto bien disfruto y punto" | Noticias de Salud en Heraldo.es](https://imagenes.heraldo.es/files/og_thumbnail_1900/uploads/imagenes/2016/06/29/_N2A3880_ef64be54.jpg)
Tengo Gaucher. No pienso en mañana, si me levanto bien disfruto y punto" | Noticias de Salud en Heraldo.es
![Dictamen Preliminar de Evaluación de Tecnología Sanitaria N° 020-SDEPFYOTS-DETS-IETSI-2019. Eficacia y seguridad de imiglucerasa para el tratamiento de pacientes con enfermedad de Gaucher tipo 1 Dictamen Preliminar de Evaluación de Tecnología Sanitaria N° 020-SDEPFYOTS-DETS-IETSI-2019. Eficacia y seguridad de imiglucerasa para el tratamiento de pacientes con enfermedad de Gaucher tipo 1](https://repositorio.essalud.gob.pe/bitstream/handle/20.500.12959/2256/DICT.%20020-SDEPFYOTS-2019.pdf.jpg?sequence=4&isAllowed=y)
Dictamen Preliminar de Evaluación de Tecnología Sanitaria N° 020-SDEPFYOTS-DETS-IETSI-2019. Eficacia y seguridad de imiglucerasa para el tratamiento de pacientes con enfermedad de Gaucher tipo 1
![Structure of acid β-glucosidase with pharmacological chaperone provides insight into Gaucher disease | Nature Chemical Biology Structure of acid β-glucosidase with pharmacological chaperone provides insight into Gaucher disease | Nature Chemical Biology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fnchembio850/MediaObjects/41589_2007_Article_BFnchembio850_Fig1_HTML.jpg)
Structure of acid β-glucosidase with pharmacological chaperone provides insight into Gaucher disease | Nature Chemical Biology
![Correction of pathology in mice displaying Gaucher disease type 1 by a clinically-applicable lentiviral vector: Molecular Therapy Methods & Clinical Development Correction of pathology in mice displaying Gaucher disease type 1 by a clinically-applicable lentiviral vector: Molecular Therapy Methods & Clinical Development](https://www.cell.com/cms/asset/2fc8dc16-7495-4dd8-93ef-6dfc50b01be7/fx1.jpg)
Correction of pathology in mice displaying Gaucher disease type 1 by a clinically-applicable lentiviral vector: Molecular Therapy Methods & Clinical Development
The Evaluation of Skeletal Manifestations in Patients with Gaucher Disease. - Document - Gale Academic OneFile
![Pharmacological Chaperones and Coenzyme Q10 Treatment Improves Mutant β-Glucocerebrosidase Activity and Mitochondrial Function in Neuronopathic Forms of Gaucher Disease | Scientific Reports Pharmacological Chaperones and Coenzyme Q10 Treatment Improves Mutant β-Glucocerebrosidase Activity and Mitochondrial Function in Neuronopathic Forms of Gaucher Disease | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fsrep10903/MediaObjects/41598_2015_Article_BFsrep10903_Fig1_HTML.jpg)
Pharmacological Chaperones and Coenzyme Q10 Treatment Improves Mutant β-Glucocerebrosidase Activity and Mitochondrial Function in Neuronopathic Forms of Gaucher Disease | Scientific Reports
![Glycosphingolipids and lysosomal storage disorders as illustrated by gaucher disease - ScienceDirect Glycosphingolipids and lysosomal storage disorders as illustrated by gaucher disease - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1367593119300869-gr2.jpg)
Glycosphingolipids and lysosomal storage disorders as illustrated by gaucher disease - ScienceDirect
![Alterations in the properties of the cell membrane due to glycosphingolipid accumulation in a model of Gaucher disease | Scientific Reports Alterations in the properties of the cell membrane due to glycosphingolipid accumulation in a model of Gaucher disease | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-017-18405-8/MediaObjects/41598_2017_18405_Fig1_HTML.jpg)
Alterations in the properties of the cell membrane due to glycosphingolipid accumulation in a model of Gaucher disease | Scientific Reports
![Feasibility of gene therapy in Gaucher disease using an adeno-associated virus vector | Journal of Human Genetics Feasibility of gene therapy in Gaucher disease using an adeno-associated virus vector | Journal of Human Genetics](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs10038-004-0186-8/MediaObjects/s10038-004-0186-8flb3.gif)
Feasibility of gene therapy in Gaucher disease using an adeno-associated virus vector | Journal of Human Genetics
![IJMS | Free Full-Text | Exploring the Pathophysiologic Cascade Leading to Osteoclastogenic Activation in Gaucher Disease Monocytes Generated via CRISPR/Cas9 Technology IJMS | Free Full-Text | Exploring the Pathophysiologic Cascade Leading to Osteoclastogenic Activation in Gaucher Disease Monocytes Generated via CRISPR/Cas9 Technology](https://pub.mdpi-res.com/ijms/ijms-24-11204/article_deploy/html/images/ijms-24-11204-g001.png?1688716071)
IJMS | Free Full-Text | Exploring the Pathophysiologic Cascade Leading to Osteoclastogenic Activation in Gaucher Disease Monocytes Generated via CRISPR/Cas9 Technology
![Neuroinflammation in neuronopathic Gaucher disease: Role of microglia and NK cells, biomarkers, and response to substrate reduction therapy | eLife Neuroinflammation in neuronopathic Gaucher disease: Role of microglia and NK cells, biomarkers, and response to substrate reduction therapy | eLife](https://iiif.elifesciences.org/lax/79830%2Felife-79830-fig9-v2.tif/full/1500,/0/default.jpg)